Home › NDC Lookup › RxCUI directory › RxCUI 1858981

North American coral snake antivenin 250 UNT Injection — RxCUI 1858981

RxNorm drug concept · Semantic clinical drug
RxCUI 1858981 Semantic clinical drug · SCD ● Current RxNorm concept 1 FDA product 1 package NDC Snapshot Jul 14, 2026

This page is curated, coded, and maintained by

Compiled from public NLM RxNorm and FDA (openFDA NDC directory) data sources. Editorial policy

What you’re looking at: the standardized identity of one medicine, as the U.S. drug-data system sees it. Below — every FDA-listed product, package code, price benchmark, and billing code that maps to it.

🗂️ Key Facts

RxCUI1858981
Official nameNorth American coral snake antivenin 250 UNT Injection
Concept typeSemantic clinical drug (SCD)
RxNorm statusCurrent RxNorm concept
Also known asNorth American coral snake antivenin 250 [arb'U] per 10 ML Injection; North American coral snake antivenin in 10 ML Injection
FDA products mapped1
Package NDCs mapped1
RxNorm release07/06/2026
Snapshot dataJul 14, 2026

🕸️ Concept Web — How North American coral snake antivenin 250 UNT Inj... Connects

One RxCUI never lives alone. Follow the path from the raw ingredient down to the exact strength-and-form concepts FDA products carry — every stop is a real RxNorm concept with its own identifier. Hover or focus any chip for what it means.
This page's concept North American coral snake antivenin 250 UNT Injection RxCUI 1858981

Every web starts here: one RxCUI, one fixed meaning in the RxNorm vocabulary.

  1. Ingredients 1

    The active substance itself — no strength, form, or brand attached yet.

    • North American coral snake antivenin 979384
  2. Dose forms 4

    The ingredient poured into a form — tablet, solution, cream — still without one fixed strength.

    • North American coral snake antivenin Injection 1858980
    • North American coral snake antivenin Injectable Product 1159858
    • Injection 1649574
    • Injectable Product 1151126
  3. Clinical & branded drugs 1

    Ingredient + strength + dose form. These are the concepts real FDA products actually carry.

    • North American coral snake antivenin 250 UNT 1858979

Showing up to 8 concepts per family — 6 of 6 stored related concepts drawn.
These are official RxNorm vocabulary relationships — how concepts name and organize the same medicine. They do not establish therapeutic equivalence or substitutability: two concepts appearing in one web is never a statement that products can be swapped.

🔀 Generic ⇄ Brand Crosswalk

The same medicine has an unbranded (generic) identity and one or more brand-name identities — each with its own RxCUI. This is a naming relationship in RxNorm, not a statement that any two products are substitutable.

Generic (Clinical) Concepts

  • North American coral snake antivenin 250 UNT SCDC · 1858979
  • North American coral snake antivenin Injection SCDF · 1858980
  • North American coral snake antivenin Injectable Product SCDG · 1159858

📦 FDA Products & Package NDCs

1 product · 1 package NDC
1 package NDC map to RxCUI 1858981 in the current snapshot — up to 50 per page. Each linked NDC opens its full package page.
Package NDC Package Brand / generic name Labeler Marketing start
00008-0423-03 1 VIAL in 1 CARTON (0008-0423-03) / 10 mL in 1 VIAL (0008-0... North American Coral Snake Antivenin (Equine) Wyeth Pharmaceuticals LLC, a subsidiary of Pfizer Inc. 2016-10-12
Observed labelers: Wyeth Pharmaceuticals LLC, a subsidiary of Pfizer Inc. (1) — this is the FDA-listed mapping footprint, not sales, inventory, availability, or market share.

🗃️ Sources & Limits

Atlas generation902fddb9-e9c1-4004-bf4c-dba4d51037c7
openFDA export observedJul 14, 2026
RxNorm release07/06/2026
Methodology2026-07-full-catalog-v1
  • A shared RxCUI does not prove interchangeability. Products mapped to the same concept are not thereby equivalent or substitutable — equivalence is a separate, product-level determination.
  • Listing here does not establish approval or coverage. Appearing in this snapshot is a data observation, not an FDA approval status or a payer coverage decision.
  • Missing data never means zero. A silent dataset (no price, no billing code, no utilization) means no observation — not that the real-world value is zero.
  • Counts describe the mapping footprint. Product, package, and labeler counts are the FDA-listed mapping footprint in this snapshot — not sales, inventory, availability, or market share.
This product uses publicly available data from the U.S. National Library of Medicine (NLM), National Institutes of Health, Department of Health and Human Services; NLM is not responsible for the product and does not endorse or recommend this or any other product.

Machine-readable JSON

Reference information about drug-concept identifiers and public regulatory data — not medical advice. Talk to your pharmacist or prescriber about your own medication.